{"organizations": [], "uuid": "8a41186458c005665886b2dd45babbf8b2c6ddc5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-acquires-exc/brief-caladrius-biosciences-acquires-exclusive-worldwide-rights-to-data-set-regulatory-filings-for-cd34-cell-therapy-program-idUSASB0C8YA", "country": "US", "domain_rank": 408, "title": "BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-06T15:03:00.000+02:00", "replies_count": 0, "uuid": "8a41186458c005665886b2dd45babbf8b2c6ddc5"}, "author": "", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-acquires-exc/brief-caladrius-biosciences-acquires-exclusive-worldwide-rights-to-data-set-regulatory-filings-for-cd34-cell-therapy-program-idUSASB0C8YA", "ord_in_thread": 0, "title": "BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program", "locations": [], "entities": {"persons": [{"name": "shire", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-caladrius biosciences acquires exclusive worldwide rights to data set", "sentiment": "negative"}, {"name": "caladrius biosciences inc", "sentiment": "none"}, {"name": "shire plc", "sentiment": "none"}, {"name": "cd34+ cell therapy program reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "caladrius biosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6, 2018 / 1:04 PM / in 11 minutes BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program Reuters Staff 1 Min Read March 6 (Reuters) - Caladrius Biosciences Inc: * CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA * CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM * CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES * CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-06T15:03:00.000+02:00", "crawled": "2018-03-06T15:19:59.000+02:00", "highlightTitle": ""}